Insider Trading at Absci: A Closer Look at Recent Transactions

Absci insiders have been net buyers of the company's stock over the past year, with the largest purchase by Andreas Busch being the biggest insider purchase in the last 12 months. Insiders own 6.3% of the company, indicating alignment between leaders and shareholders. Despite the company's losses, insiders' confidence in the future is evident.

Absci Corporation (NASDAQ: ABSI) has seen insiders actively acquiring the company's stock, with the largest purchase by Andreas Busch being the most significant insider transaction in the past 12 months. This trend underscores insiders' confidence in Absci's future prospects despite recent financial setbacks.

On Monday, July 28th, Andreas Busch, an insider at Absci, purchased 50,000 shares of the company's stock at an average price of $3.04 per share, totaling $152,000.00. Following this purchase, Busch owned 327,264 shares, valued at $994,882.56, representing an 18.03% increase in his ownership stake [1].

Insiders' ownership of Absci stock stands at 6.3%, indicating a significant alignment between company leaders and shareholders. This alignment is particularly notable given the company's recent earnings report, where Absci reported a loss of ($0.21) per share for its latest quarter, surpassing analysts' estimates by $0.02 [1]. Despite these losses, insiders' continued buying suggests a belief in Absci's long-term potential, particularly in its AI-driven drug discovery platform.

The company's strategic pivot from a pure AI platform to a clinical-stage biopharmaceutical company has required significant capital. Absci has announced a proposed public offering of $50 million in common stock, with an additional $7.5 million option for underwriters. This capital raise will support the advancement of internal drug programs, continued investment in the Integrated Drug Creation platform, and general corporate purposes [2].

Institutional investors have also shown interest in Absci, with several large investors acquiring new positions in the company's stock during the first and fourth quarters of 2025. For instance, Cambridge Investment Research Advisors Inc. and Neuberger Berman Group LLC each acquired positions valued at about $26,000, while BNP Paribas Financial Markets acquired a position worth approximately $28,000 during the fourth quarter [1].

Wall Street analysts have mixed views on Absci's stock, with five analysts rating it as a "buy" and one assigning a "sell" rating. The average rating is "Moderate Buy," with a consensus price target of $8.28 [1]. Despite the mixed sentiment, insiders' recent stock purchases and the company's strategic pivot highlight a belief in Absci's potential to deliver significant growth through its AI-driven drug discovery platform.

References:
[1] https://www.marketbeat.com/instant-alerts/absci-corporation-nasdaqabsi-insider-acquires-15200000-in-stock-2025-07-29/
[2] https://www.stocktitan.net/news/ABSI/absci-announces-proposed-public-offering-of-common-iry1qiblr8hg.html